Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (noted as Chemomab Therapeutics Ltd. in metadata) covers the period ending August 5, 2019. The filing serves to announce the company's second quarter 2019 financial results, incorporating a press release dated August 5, 2019, as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a cover sheet referencing an attached press release for detailed financial data, which is not included in the provided text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of Q2 2019 results.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the referenced press release (Exhibit 99.1), the content of which is not present in the source text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to obtain actual Q2 2019 financial figures.
- Confirm the correct registrant name, as the metadata lists "Chemomab Therapeutics Ltd." while the filing text identifies "Anchiano Therapeutics Ltd."
- Review the attached press release for specific details on cash burn, runway, and clinical trial progress, as these are absent from the Form 6-K cover text.